Markets
MarketMind AI
Baskets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
All Features
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
Charts & Report
Charts and Graphs
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Price History/Seasonality
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Aurobindo Pharma Ltd.
NSE: AUROPHARMA
|
BSE: 524804
|
ISIN: INE406A01037
|
Industry: Pharmaceuticals
US FDA Approval
|
Strong Performer, Getting Expensive
1446.0000
-16.30
(
-1.11
%)
NSE
Jun 08, 2026
15:29 PM
42.31% Gain from 52W Low
Volume:
506.6K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Aurobindo Pharma Ltd.
07 Nov 2025, 12:00AM
US FDA Approval
1446.00
-1.11%
Result Update:Aurobindo Pharma
Buy:
Aurobindo Pharma Ltd.
by
Axis Direct
Target: 1345 | Target met
Target
Axis Direct
We maintain our BUY recommendation on the stock with a TP of Rs 1,345/share.
Number of FII/FPI investors increased from 698 to 749 in Mar 2026 qtr.
More from Aurobindo Pharma Ltd.
Recommended
Market trades lower, Fortis Healthcare rises amid reports of new drug scheme
Trendlyne Marketwatch |
08 Jun 2026, 03:33PM
Five Interesting Stocks Today - June 5, 2026
The Baseline |
05 Jun 2026
A deal is called off, increasing the chance for Aurobindo Pharma to be debt free
|
15 Jul 2020